Two preventive tools — a maternal vaccine and a monoclonal antibody — were tied to a recent drop in RSV hospitalization rates for U.S. babies.

As winter nears and the cold and flu season sets in, the highly infectious respiratory virus RSV has again begun its spread. So far this year, the National Disease Surveillance System (NDSS ...

RSV prevention products led to a significant reduction in hospitalization rates for infants aged 0 to 7 months during the 2024-2025 season. The maternal RSV vaccine and nirsevimab were key ...

Compared with 2018-2020 pooled rates, 2024-2025 RSV-associated hospitalization rates were lower among infants aged 0 to 7 months. HealthDay News — Maternal respiratory syncytial virus (RSV ...

Cumulatively, the efficacy of a single Arexvy dose to prevent RSV-related lower respiratory tract disease over three RSV seasons was 62.9%. Efficacy over three seasons was 51.1%.

The Therapeutic Goods Association recently expanded approval for the RSV vaccine AREXVY to include Australians aged 50 and older with chronic health and respiratory conditions. Vulnerable people ...

Nirsevimab associated with lower odds of RSV-related hospitalization, ICU admission, lower respiratory tract infection incidence. HealthDay News — Nirsevimab is effective for reducing the burden ...

A landmark global trial shows that one dose of the RSVPreF3 OA vaccine protects older adults against serious RSV lung disease for three seasons, raising hopes for long-term protection with just a ...

Children with severe RSV "are essentially drowning in their own mucus," says Carlos Oliveira, MD, Ph.D., assistant professor of pediatrics (infectious diseases) at YSM and senior author of the study.

But before everyone really panicked, the “Missing” billboard revealed itself to be a campaign, a thought-provoking advocacy effort to raise awareness about Respiratory Syncytial Virus (RSV).